Aptose Biosciences (APTO) News Today $0.25 +0.00 (+0.48%) (As of 12/24/2024 05:19 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.comDecember 23 at 2:11 AM | americanbankingnews.comWall Street Set to Open Lower Friday; Key Inflation Data Lower Than ExpectedDecember 20, 2024 | msn.comAptose Biosciences, Inc.: Aptose Announces Positive Decision by Nasdaq Hearings PanelDecember 20, 2024 | finanznachrichten.deAptose Biosciences (NASDAQ: APTO) Announces Regulation FD DisclosureOn December 19, 2024, Aptose Biosciences Inc. issued a press release, providing detailed information on recent developments. The press release specified various financial results andDecember 20, 2024 | americanbankingnews.comAptose Biosciences granted extension to regain compliance with NasdaqDecember 19, 2024 | markets.businessinsider.comAptose Announces Positive Decision by Nasdaq Hearings PanelDecember 19, 2024 | globenewswire.comAptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with VenetoclaxDecember 12, 2024 | globenewswire.comPromising Potential of Aptose Biosciences in AML Treatment Drives Buy RatingDecember 11, 2024 | markets.businessinsider.comAptose Biosciences announces clinical data on tuspetinibDecember 9, 2024 | markets.businessinsider.comAptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AMLDecember 9, 2024 | globenewswire.comStrategic Collaboration and Promising Pipeline Drive Buy Rating for Aptose BiosciencesDecember 6, 2024 | markets.businessinsider.comAptose Biosciences signs CRADA with NCI to develop tuspetinib for AML, MDSDecember 4, 2024 | markets.businessinsider.comAptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine TrialsDecember 3, 2024 | financialpost.comAptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine TrialsDecember 3, 2024 | globenewswire.comWilliam G. Rice Purchases 100,000 Shares of Aptose Biosciences Inc. (NASDAQ:APTO) StockNovember 27, 2024 | insidertrades.comAptose Biosciences Inc. Announces Closing of $8 Million Public OfferingNovember 25, 2024 | financialpost.comAptose Biosciences Inc. Announces Closing of $8 Million Public OfferingNovember 25, 2024 | financialpost.comAptose Biosciences Inc. Announces Closing of $8 Million Public OfferingNovember 25, 2024 | globenewswire.comAptose Biosciences to sell 40M shares at 20c in public offeringNovember 23, 2024 | markets.businessinsider.comAptose Biosciences Inc. Announces Pricing of $8 Million Public OfferingNovember 22, 2024 | globenewswire.comAptose Biosciences, Inc.: Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet TherapyNovember 21, 2024 | finanznachrichten.deAptose Biosciences initiates TUSCANY Phase 1/2 studyNovember 21, 2024 | markets.businessinsider.comAptose Biosciences price target lowered to $2 from $7 at H.C. WainwrightNovember 21, 2024 | markets.businessinsider.comAptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet TherapyNovember 20, 2024 | globenewswire.comAptose Biosciences Reports Q3 2024 Financial HighlightsNovember 9, 2024 | markets.businessinsider.comAptose Biosciences Advances AML Triplet TherapyNovember 9, 2024 | markets.businessinsider.comAptose Reports Results for the Third Quarter 2024November 8, 2024 | globenewswire.comAptose Biosciences Inc (LTI.BE)September 12, 2024 | sg.finance.yahoo.comAptose Announces Results from Special Meeting of ShareholdersSeptember 5, 2024 | globenewswire.comWall Street Set to Open Shortened Week Lower Tuesday as Investors Await Manufacturing DataSeptember 4, 2024 | msn.comAptose Biosciences secures funds for AML treatment developmentSeptember 3, 2024 | finance.yahoo.comAptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop TuspetinibAugust 30, 2024 | globenewswire.comAptose Biosciences Inc: Analyst Forecasts and Stock AnalysisAugust 30, 2024 | theglobeandmail.comAptose Announces Adjournment of its Special Meeting of ShareholdersAugust 15, 2024 | globenewswire.comADMA Biologics Shares Rise 27% After 2Q Earnings Beat ExpectationsAugust 9, 2024 | marketwatch.comAptose Reports Results for the Second Quarter 2024August 8, 2024 | globenewswire.comAptose Announces Receipt of Deficiency Notice from NasdaqJuly 19, 2024 | globenewswire.comAptose Announces Results from Annual and Special Meeting of ShareholdersJune 18, 2024 | globenewswire.comAptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid CongressJune 14, 2024 | globenewswire.comAptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJune 3, 2024 | globenewswire.comAptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 31, 2024 | globenewswire.comAptose Reports Results for the First Quarter 2024May 14, 2024 | globenewswire.comAptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024May 6, 2024 | globenewswire.comAptose Biosciences target cut, maintains buy rating on new drug developmentMarch 29, 2024 | investing.comAptose Biosciences, Inc.: Aptose Reports Results for the Fourth Quarter and Full Year 2023March 28, 2024 | finanznachrichten.deAptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finance.yahoo.comEdgewood secures $20m in Series A for clinical development of cancer therapyMarch 27, 2024 | msn.comRecap: Aptose Biosciences Q4 EarningsMarch 27, 2024 | benzinga.comAptose Reports Results for the Fourth Quarter and Full Year 2023March 26, 2024 | globenewswire.comAptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024March 18, 2024 | globenewswire.com Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter. Email Address $19 for a FULL YEAR of stock picks?! (Ad)We're offering you the chance to subscribe to Behind the Markets for an ENTIRE YEAR for just $19. But why? Because there is a very small window of time... as little as 25 days from now... That will change the market forever. Click here to get in now>>> APTO Media Mentions By Week APTO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APTO News Sentiment▼0.080.66▲Average Medical News Sentiment APTO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APTO Articles This Week▼71▲APTO Articles Average Week Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Invivyd News Today Dyadic International News Today AlloVir News Today CEL-SCI News Today Omega Therapeutics News Today Achilles Therapeutics News Today Passage Bio News Today Estrella Immunopharma News Today SAB Biotherapeutics News Today Surrozen News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APTO) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredBuy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
